Quantbot Technologies LP Sells 35,348 Shares of Johnson & Johnson $JNJ

Quantbot Technologies LP decreased its position in Johnson & Johnson (NYSE:JNJ) by 84.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,653 shares of the company’s stock after selling 35,348 shares during the quarter. Quantbot Technologies LP’s holdings in Johnson & Johnson were worth $1,234,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in the company. Abich Financial Wealth Management LLC purchased a new position in shares of Johnson & Johnson in the 3rd quarter worth approximately $26,000. Evolution Wealth Management Inc. purchased a new position in Johnson & Johnson in the second quarter worth $27,000. Clayton Financial Group LLC bought a new position in Johnson & Johnson in the 3rd quarter valued at $28,000. Semmax Financial Advisors Inc. increased its position in shares of Johnson & Johnson by 55.0% during the 2nd quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock valued at $31,000 after purchasing an additional 72 shares during the last quarter. Finally, Compass Financial Services Inc raised its stake in shares of Johnson & Johnson by 707.1% during the 3rd quarter. Compass Financial Services Inc now owns 226 shares of the company’s stock worth $42,000 after purchasing an additional 198 shares during the period. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Price Performance

NYSE JNJ opened at $239.65 on Friday. The company has a 50-day moving average price of $227.70 and a 200-day moving average price of $203.56. Johnson & Johnson has a 52 week low of $141.50 and a 52 week high of $251.71. The company has a quick ratio of 0.77, a current ratio of 1.03 and a debt-to-equity ratio of 0.48. The firm has a market capitalization of $577.53 billion, a P/E ratio of 21.69, a PEG ratio of 2.42 and a beta of 0.34.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Saturday, January 31st. The company reported $2.46 earnings per share (EPS) for the quarter. Johnson & Johnson had a net margin of 28.46% and a return on equity of 33.04%. The company had revenue of $24.28 billion during the quarter. Equities research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Tuesday, February 24th will be given a dividend of $1.30 per share. The ex-dividend date is Tuesday, February 24th. This represents a $5.20 annualized dividend and a yield of 2.2%. Johnson & Johnson’s payout ratio is 47.06%.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Timothy Schmid sold 1,322 shares of the firm’s stock in a transaction that occurred on Friday, February 20th. The shares were sold at an average price of $245.66, for a total transaction of $324,762.52. Following the sale, the executive vice president owned 25,447 shares in the company, valued at approximately $6,251,310.02. This trade represents a 4.94% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Vanessa Broadhurst sold 6,197 shares of Johnson & Johnson stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $243.39, for a total transaction of $1,508,287.83. Following the transaction, the executive vice president directly owned 23,003 shares in the company, valued at $5,598,700.17. This represents a 21.22% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 30,142 shares of company stock valued at $7,360,528. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson News Roundup

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: FDA approval for TECVAYLI® (teclistamab) in combination with DARZALEX FASPRO® for relapsed/refractory multiple myeloma expands J&J’s label into earlier lines of therapy, with Phase 3 data showing significant progression?free and overall survival benefits — a potential new standard of care and meaningful long?term revenue upside for the oncology portfolio. PR Newswire: TECVAYLI + DARZALEX approval Reuters: FDA approves JNJ blood cancer drug
• Neutral Sentiment: JPMorgan raised its price target to $250 but kept a “neutral” rating — the higher target signals upside potential acknowledged by analysts, yet the maintained rating tempers immediate buy-side enthusiasm. Benzinga / TickerReport: JPMorgan price target
• Neutral Sentiment: J&J launched a direct?to?consumer website to sell certain drugs to uninsured or out?of?pocket U.S. patients — a strategic move to improve access and potentially capture incremental retail revenue, though initial impact on top line is uncertain. Reuters: direct-to-consumer site
• Neutral Sentiment: Pipeline progress: J&J is advancing nipocalimab (Fast Track for SLE) with Phase 3 underway — positive R&D momentum that supports future growth, offset by competing legal/claim disputes noted in coverage. Yahoo Finance: nipocalimab progress & legal challenge
• Negative Sentiment: Two J&J units agreed to pay $65 million to settle a Tracleer antitrust class action alleging overcharges — a direct legal expense and reminder of ongoing litigation risks, though the amount is modest versus J&J’s market cap. Reuters: $65M Tracleer settlement
• Negative Sentiment: Market reaction: coverage notes J&J shares declined more than the broader market during the session, reflecting that investors are weighing legal/settlement headlines and profit?taking despite the positive FDA news. Zacks: JNJ declines more than market

Analyst Upgrades and Downgrades

JNJ has been the subject of a number of research analyst reports. HSBC raised their price objective on shares of Johnson & Johnson from $240.00 to $265.00 and gave the stock a “buy” rating in a report on Friday, January 30th. Stifel Nicolaus increased their target price on shares of Johnson & Johnson from $205.00 to $220.00 and gave the stock a “hold” rating in a research report on Thursday, January 22nd. Bank of America reissued a “neutral” rating on shares of Johnson & Johnson in a research report on Monday. Loop Capital set a $220.00 price objective on shares of Johnson & Johnson in a report on Tuesday, January 27th. Finally, Royal Bank Of Canada boosted their target price on shares of Johnson & Johnson from $240.00 to $255.00 and gave the company an “outperform” rating in a report on Tuesday, February 3rd. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $234.87.

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.